Search
Anke Biotechnology: PA3-17 Injection by Biosyngen Included in List of Proposed Breakthrough Therapies
3 week ago /
Read about 0 minute
Author：小编
Biosyngen, a company associated with Anke Biotechnology, has had its independently developed PA3-17 injection included in the list of proposed breakthrough therapies published by the Center for Drug Evaluation of the National Medical Products Administration. This injection represents the world's first autologous CAR-T cell therapy product targeting CD7, specifically designed for the treatment of adult relapsed/refractory T-lymphoblastic leukemia/lymphoma. Having completed Phase I registration clinical trials, the drug has demonstrated remarkable efficacy with a best objective response rate of up to 84.6%, alongside manageable safety profiles.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
